Quadrant Capital Group’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,350
| Closed | -$19.5K | – | 1713 |
|
|
2026
Q1 | $19.5K | Hold |
1,350
| – | – | ﹤0.01% | 2004 |
|
|
2025
Q4 | $19.2K | Hold |
1,350
| – | – | ﹤0.01% | 2010 |
|
|
2025
Q3 | $10.6K | Buy |
+1,350
| New | +$9.61K | ﹤0.01% | 2145 |
|
|
2024
Q4 | – | Sell |
-14
| Closed | -$150 | – | 2758 |
|
|
2024
Q3 | $150 | Hold |
14
| – | – | ﹤0.01% | 2719 |
|
|
2024
Q2 | $139 | Hold |
14
| – | – | ﹤0.01% | 2683 |
|
|
2024
Q1 | $165 | Sell |
14
-125
| -90% | -$1.6K | ﹤0.01% | 2700 |
|
|
2023
Q4 | $1.97K | Buy |
+139
| New | +$1.58K | ﹤0.01% | 2476 |
|
|
2023
Q3 | – | Sell |
-725
| Closed | -$9.11K | – | 2715 |
|
|
2023
Q2 | $9.11K | Hold |
725
| – | – | ﹤0.01% | 2032 |
|
|
2023
Q1 | $8.04K | Buy |
+725
| New | +$8.94K | ﹤0.01% | 2112 |
|
|
2022
Q3 | – | Sell |
-28
| Closed | – | – | 2694 |
|
|
2022
Q2 | $0 | Sell |
28
-640
| -96% | -$5.27K | ﹤0.01% | 2596 |
|
|
2022
Q1 | $6K | Hold |
668
| – | – | ﹤0.01% | 1844 |
|
|
2021
Q4 | $8K | Sell |
668
-83
| -11% | -$925 | ﹤0.01% | 1713 |
|
|
2021
Q3 | $7K | Buy |
751
+67
| +10% | +$685 | ﹤0.01% | 1747 |
|
|
2021
Q2 | $7K | Hold |
684
| – | – | ﹤0.01% | 1721 |
|
|
2021
Q1 | $7K | Sell |
684
-20
| -3% | -$310 | ﹤0.01% | 1643 |
|
|
2020
Q4 | $16K | Hold |
704
| – | – | ﹤0.01% | 1187 |
|
|
2020
Q3 | $10K | Buy |
704
+20
| +3% | +$292 | ﹤0.01% | 1222 |
|
|
2020
Q2 | $10K | Hold |
684
| – | – | ﹤0.01% | 1324 |
|
|
2020
Q1 | $6K | Sell |
684
-167
| -20% | -$1.59K | ﹤0.01% | 1580 |
|
|
2019
Q4 | $8K | Buy |
+851
| New | +$7.79K | ﹤0.01% | 1956 |
|
Other funds holding FOLD
Quadrant Capital Group's FOLD Position: Q2 2026 in Review
Quadrant Capital Group sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 1,350 shares — an estimated $19.5K sold.
Quadrant Capital Group first reported a position in FOLD in Q4 2019 and held it in 20 quarters. The position peaked at $19.5K in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Quadrant Capital Group reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Quadrant Capital Group sold 1,350 Amicus Therapeutics shares in Q2 2026, an estimated $19.5K.
- Quadrant Capital Group first reported a position in Amicus Therapeutics in Q4 2019 and held it in 20 quarters.
- Quadrant Capital Group's Amicus Therapeutics position peaked at $19.5K in Q1 2026.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.